SKIBSTED RUSSELL 4

What Happened SKIBSTED RUSSELL, Processa Pharmaceuticals' (PCSA) Chief Financial Officer, made an open-market purchase of 2,654 common shares on 2026-06-15. The shares were acquired at $2.22 per share for a total cash outlay of $5,892. This was a direct purchase (transaction code P), which is a straightforward acquisition rather than a sale or option exercise.

Key Details

• Transaction date and price: 2026-06-15, 2,654 shares at $2.22 each.
• Total value: $5,892.
• Transaction type: Open-market purchase (Code P).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes/plan: Filing includes no 10b5-1 plan, tax withholding, or other special footnotes.
• Timeliness: Filed on 2026-06-16 (one business day after the transaction), which is timely under Form 4 rules.

Context Insider purchases can be more informative than sales because they represent insiders committing personal capital. This purchase is relatively small in dollar terms, so while it is a positive signal that the CFO added shares, its size may limit how much weight investors place on it. The filing provides no additional notes indicating a pre-arranged trading plan or a related disposition.